The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Travoprost
travoprost · TRAVOPROST .04 mg/mL · Solution · Ophthalmic · Golden State Medical Supply, Inc.
NDC 51407-0731-25 · 1 BOTTLE in 1 CARTON / 2.5 mL in 1 BOTTLE · ANDA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Part D plans paid (avg)$30.77per dosage unitgross, before rebates — matched by drug name · 2024
- Federal contracts pay (FSS)$17.46per package of 2.5MLGolden State Medical Supply, Inc. · May 10, 2024
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for travoprost (other) in the next 90 days
OAI inspection at a producing facility (24 months) · sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- Golden State Medical Supply Inc.United Statesrelabel · repack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Regulatory
- Application
- ANDA203431
- TE code
- AT2
- Approval date
- Jul 10, 2015
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class II · TerminatedMay 25, 2023Golden State Medical Supply Inc. — Lack of Assurance of Sterility: Tamper Evidence Seal is missing on secondary container.
Manufacturers of travoprost (Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Apotex Corp. | TRAVOPROST .04 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Golden State Medical Supply, Inc. | TRAVOPROST .04 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Travoprost — NDC 51407-0731-25," retrieved September 3, 2026, https://drugdashboards.com/drug/51407073125.
Free to cite with attribution — see how the data is put together.